Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dipyridamole + aspirin
- Development stage
- Approved
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Dipyridamole + aspirin** is an oral fixed-dose antiplatelet combination, most widely marketed as Aggrenox. Each capsule contains extended-release dipyridamole 200 mg plus immediate-release aspirin 25 mg. Aspirin irreversibly inhibits platelet cyclooxygenase-1, suppressing thromboxane A2 production, while dipyridamole inhibits adenosine uptake and cyclic-nucleotide phosphodiesterase activity, increasing extracellular adenosine and platelet cyclic nucleotide signaling to reduce platelet activation and aggregation. It is approved for secondary prevention of stroke in patients with a prior transient ischemic attack or completed ischemic stroke due to thrombosis. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f07c8535-f9fb-4697-9b63-1ab22210efc9))
- Brand names
- AggrenoxAsasantinAsasantin Retard
- Other names
- acetylsalicylic acid + dipyridamoleacetylsalicylic acid/dipyridamoleaspirin + dipyridamoleaspirin + extended-release dipyridamoleaspirin/dipyridamoleaspirin/extended-release dipyridamoledipyridamole + acetylsalicylic acidextended-release dipyridamole + aspirin
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)ENT1 (Solute carrier family 29 member 1)PDE5 (Phosphodiesterase 5A)PDE (Phosphodiesterase family)
Beyond the preview
Go deeper on dipyridamole + aspirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dipyridamole + aspirin.